SCHEMBL7336152

SCHEMBL7336152

O=C(O)Cc1ccc(Cl)cc1OCC(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
CHRM1 P11229 1/20 0.48
EPHX2 P34913 1/20 0.43
MGLL Q99685 2/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.41
CAMK2A Q9UQM7 2/20 0.41
POLQ O75417 1/20 0.40
MRGPRX1 Q96LB2 1/20 0.40
CXCL8 P10145 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7335722 0.88 MAPT (0.52) KDM2BKDM4CCHRM1EPHX2MAPT
SCHEMBL8081337 0.84 CAMK2A (0.56) KDM2BKDM4CMAPTCAMK2ACXCL8
SCHEMBL7344505 0.84 CXCL8 (0.44) KDM2BKDM4CMGLLMAPTCAMK2A
SCHEMBL7340892 0.84 RXRA (0.47) MGLLMAPTPTGDR2KDM4E
SCHEMBL15778596 0.81 KDM2B (0.45) KDM2BKDM4CEPHX2MGLLMAPT
Hydrochloric Acid SCHEMBL7339634 0.81 ALDH1A1 (0.42) KDM2BKDM4CMAPTPTGDR2CAMK2A
SCHEMBL21900449 0.80 CHRM1 (0.51) KDM4CCHRM1MAPTTDP1KEAP1
SCHEMBL8092961 0.79 KDM4E (0.45) MAPTCAMK2AMEN1KMT2AKDM4E
SCHEMBL18641892 0.79 CHRM1 (0.50) CHRM1MAPTTDP1KEAP1NFE2L2
SCHEMBL7333637 0.78 CXCL8 (0.55) CHRM1MAPTTDP1CXCL8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
US-5968938-A Piperazine oxytocin receptor antagonists MERCK & CO., INC. (US) 1999-10-19 US disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 KDM2B 4001/4885KDM4C 4512/4885CHRM1 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.